MX2009012789A - Composiciones farmaceuticas no acuosas estables. - Google Patents

Composiciones farmaceuticas no acuosas estables.

Info

Publication number
MX2009012789A
MX2009012789A MX2009012789A MX2009012789A MX2009012789A MX 2009012789 A MX2009012789 A MX 2009012789A MX 2009012789 A MX2009012789 A MX 2009012789A MX 2009012789 A MX2009012789 A MX 2009012789A MX 2009012789 A MX2009012789 A MX 2009012789A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
aqueous pharmaceutical
stable non
hyperglycaemia
semi
Prior art date
Application number
MX2009012789A
Other languages
English (en)
Spanish (es)
Inventor
Svend Havelund
Simon Bjerregaard Jensen
Florian Anders Foeger
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2009012789A publication Critical patent/MX2009012789A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2009012789A 2007-06-01 2008-05-30 Composiciones farmaceuticas no acuosas estables. MX2009012789A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07109435 2007-06-01
EP07114524 2007-08-17
PCT/EP2008/056689 WO2008145730A1 (en) 2007-06-01 2008-05-30 Stable non-aqueous pharmaceutical compositions

Publications (1)

Publication Number Publication Date
MX2009012789A true MX2009012789A (es) 2009-12-10

Family

ID=39764679

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012789A MX2009012789A (es) 2007-06-01 2008-05-30 Composiciones farmaceuticas no acuosas estables.

Country Status (11)

Country Link
US (3) US20100190706A1 (enExample)
EP (4) EP2497462A1 (enExample)
JP (2) JP5675347B2 (enExample)
KR (1) KR20100017667A (enExample)
CN (1) CN101677944A (enExample)
AU (1) AU2008257505B2 (enExample)
BR (1) BRPI0812354A2 (enExample)
CA (1) CA2716159A1 (enExample)
MX (1) MX2009012789A (enExample)
RU (1) RU2472492C2 (enExample)
WO (2) WO2008145730A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029512T2 (en) 2006-09-22 2017-03-28 Novo Nordisk As Protease Resistant Insulin Analogs
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
US20100190706A1 (en) * 2007-06-01 2010-07-29 Novo Nordisk A/S Stable Non-Aqueous Pharmaceutical Compositions
JP5762001B2 (ja) * 2008-03-14 2015-08-12 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化インスリンアナログ
WO2009115469A1 (en) 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
JP2013504610A (ja) * 2009-09-16 2013-02-07 ノヴォ ノルディスク アー／エス インスリンを含む安定な非水性液体医薬組成物
WO2011064316A2 (en) 2009-11-25 2011-06-03 Paolo Botti Mucosal delivery of peptides
EP2523655A2 (en) * 2010-01-12 2012-11-21 Novo Nordisk A/S Pharmaceutical compositions for oral administration of insulin peptides
US20120035103A1 (en) * 2010-01-29 2012-02-09 Pillion Dennis J Method for administration of insulin and pharmaceutical composition thereof
US20130157939A1 (en) * 2010-08-23 2013-06-20 Shmuel Ben-Sasson Compositions for gastric delivery of active agents
EP2526971A1 (en) 2011-05-25 2012-11-28 ArisGen SA Mucosal delivery of drugs
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
US8853189B2 (en) 2012-05-31 2014-10-07 Prima Innovations, Llc Antispasmodic 1,2-Diols and 1,2,3-triols
WO2014124096A1 (en) * 2013-02-06 2014-08-14 Perosphere Inc. Stable glucagon formulations
AU2014333979B2 (en) 2013-10-07 2018-02-15 Novo Nordisk A/S Novel derivative of an insulin analogue
EP2946788A1 (en) 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
EP3154568A4 (en) * 2014-06-10 2018-01-24 California Institute of Technology Non-canonical insulins and their uses
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
ES2886837T3 (es) 2016-12-16 2021-12-21 Novo Nordisk As Composiciones farmacéuticas que contienen insulina
US20200155648A1 (en) * 2017-06-28 2020-05-21 Children's Medical Center Corporation Promoting lung growth
EP3915571A1 (en) * 2020-05-29 2021-12-01 Adocia Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
CN114432424B (zh) * 2021-12-27 2023-06-27 南通联亚药业股份有限公司 一种稳定的铝塑包装去氨加压素片剂
CN117045634B (zh) * 2022-05-06 2025-10-10 北京康蒂尼药业股份有限公司 一种二肽衍生物组合物及其制备方法和用途
CN120676958A (zh) * 2022-12-04 2025-09-19 吉洛法姆有限责任公司 门冬胰岛素组合物（实施方式）

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3003A (en) * 1843-03-17 Improvement in the method of propelling vessels by means of continuous streams of water
US6074A (en) 1849-01-30 Machine fob making suspender-buckles
US4468A (en) 1846-04-25 Improvement in casting spoons
US221A (en) 1837-06-03 Steam-boii
US2832685A (en) * 1952-05-24 1958-04-29 Crest Foods Co Inc Solubilization of milk proteins
US3528960A (en) * 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3950517A (en) * 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
US3869437A (en) * 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4033941A (en) * 1975-12-17 1977-07-05 Eli Lilly And Company Process for purifying glucagon
JPS6030650B2 (ja) * 1979-10-26 1985-07-17 日本油脂株式会社 座薬基剤組成物
US4468221A (en) 1981-04-10 1984-08-28 Parker-Hannifin Corporation Medication infusion pump
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4719655A (en) * 1986-01-21 1988-01-19 Dean S Brooks Invalid transfer device
US4849227A (en) * 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
US5266310A (en) * 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
AU641631B2 (en) 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
DE3844211A1 (de) * 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
KR930001305B1 (ko) * 1989-10-19 1993-02-25 니뽕 유우시 가부시끼가이샤 당 응답형 고분자 복합체(Polymer Complexes of Sugar Response Type)
US5179189A (en) * 1990-01-19 1993-01-12 Nova Pharmaceutical Corporation Fatty acid terminated polyanhydrides
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
JP3698721B2 (ja) * 1993-02-23 2005-09-21 ジェネンテク・インコーポレイテッド 有機溶媒を用いて処理したポリペプチドの賦形剤安定化
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
DE122006000015I1 (de) 1993-06-21 2006-06-29 Novo Nordisk As Asp-B28-Insulinkristalle
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
SI0792290T1 (en) 1993-09-17 2001-12-31 Novo Nordisk As Acylated insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) * 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US6500645B1 (en) * 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US20030104981A1 (en) * 1995-11-03 2003-06-05 Jelena Mandic Human insulin analogues
ZA9610374B (en) 1995-12-11 1997-06-23 Elan Med Tech Cartridge-based drug delivery device
US6451970B1 (en) * 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5981489A (en) * 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
DE59711533D1 (de) * 1996-07-26 2004-05-27 Aventis Pharma Gmbh Insulinderivate mit erhöhter Zinkbindung
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
US5957895A (en) 1998-02-20 1999-09-28 Becton Dickinson And Company Low-profile automatic injection device with self-emptying reservoir
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
US7030083B2 (en) * 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
US6660715B2 (en) 1998-11-19 2003-12-09 Massachusetts Institute Of Technology Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
US7425541B2 (en) * 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
WO2000047203A1 (en) * 1999-02-12 2000-08-17 Mqs, Inc. Formulation and system for intra-oral delivery of pharmaceutical agents
CN1141974C (zh) * 2000-06-07 2004-03-17 张昊 结肠定位释放的口服生物制剂
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
CN1160122C (zh) * 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
EP1423136A4 (en) * 2001-08-10 2007-07-25 Epix Pharm Inc POLYPEPTIDE CONJUGATES WITH EXTENDED CIRCULAR HALF TIME
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
EP1456371A1 (en) * 2001-12-05 2004-09-15 Dow Global Technologies Inc. Method for immobilizing a biologic in a polyurethane-hydrogel composition, a composition prepared from the method, and biomedical applications
UA46669C2 (uk) * 2001-12-29 2005-12-15 Товариство З Обмеженою Відповідальністю "Мако" Спосіб приготування готової лікарської форми інсуліну пролонгованої дії
ATE350425T1 (de) 2002-03-18 2007-01-15 Bespak Plc Dichtungsmaterial für eine spenderapparatur
AU2003236521A1 (en) * 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
AU2003272347A1 (en) * 2002-09-17 2004-04-08 Merck And Co., Inc. Removal of aldehyde impurity by reactive polystyrene resin
WO2004105790A1 (en) * 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
EP2107069B1 (en) * 2003-08-05 2013-01-16 Novo Nordisk A/S Novel insulin derivatives
PT1687019T (pt) * 2003-11-20 2018-02-26 Novo Nordisk As Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
JP5697831B2 (ja) 2003-12-03 2015-04-08 ノヴォ ノルディスク アー／エス 単鎖インシュリン
WO2005058961A2 (en) * 2003-12-12 2005-06-30 Amgen Inc. Antibodies specific for human galanin, and uses thereof
WO2006097793A2 (en) * 2004-04-15 2006-09-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
CN101151048A (zh) * 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
CN103223160B (zh) * 2004-07-19 2015-02-18 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
US20100298213A1 (en) 2004-08-20 2010-11-25 Novo Nordisk A/S Pharmaceutically Active Insulin Receptor-Modulating Molecules
EP1909824B1 (en) * 2005-04-08 2011-05-18 Amylin Pharmaceuticals, Inc. Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
WO2007004948A1 (en) * 2005-06-30 2007-01-11 Astrazeneca Ab Environmental detector
ATE471144T1 (de) * 2005-10-20 2010-07-15 Mdrna Inc Intranasale verabreichung von schnell wirkendem insulin
HUE029512T2 (en) 2006-09-22 2017-03-28 Novo Nordisk As Protease Resistant Insulin Analogs
US20100190706A1 (en) * 2007-06-01 2010-07-29 Novo Nordisk A/S Stable Non-Aqueous Pharmaceutical Compositions
US20090087484A1 (en) * 2007-09-28 2009-04-02 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
WO2010060667A1 (en) * 2008-11-28 2010-06-03 Novo Nordisk A/S Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides

Also Published As

Publication number Publication date
CA2716159A1 (en) 2008-12-04
JP2010529004A (ja) 2010-08-26
WO2008145730A1 (en) 2008-12-04
EP2164459A1 (en) 2010-03-24
AU2008257505A1 (en) 2008-12-04
US20100144592A1 (en) 2010-06-10
EP2497462A1 (en) 2012-09-12
CN101677944A (zh) 2010-03-24
KR20100017667A (ko) 2010-02-16
RU2472492C2 (ru) 2013-01-20
US20140349924A1 (en) 2014-11-27
US20100190706A1 (en) 2010-07-29
EP2514407A1 (en) 2012-10-24
JP5675347B2 (ja) 2015-02-25
JP2010529956A (ja) 2010-09-02
EP2164458A1 (en) 2010-03-24
BRPI0812354A2 (pt) 2015-01-27
RU2009146883A (ru) 2011-07-20
JP5628026B2 (ja) 2014-11-19
WO2008145732A1 (en) 2008-12-04
AU2008257505B2 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
Pérez et al. Gemini surfactants from natural amino acids
HK1203357A1 (en) Fibroblast growth factor 21 proteins
HK1214832A1 (zh) 用於代謝病症和疾病治療的組合物和方法
UA104605C2 (uk) Аналоги глюкагону
GEP20146056B (en) Acylated glucagon analogues
MX2011013903A (es) Polipeptidos quimericos y usos de los mismos.
BRPI0916515B8 (pt) polipeptídeo de fator estimulante de colônias de granulócitos bovino (bg-csf), formulação farmacêutica e composição compreendendo o mesmo
MX2014015258A (es) Variantes del factor 21 de crecimiento de fibroblasto.
BR112012017345A2 (pt) "composições e métodos de pgl para a produção aumentada de isopreno e outros produtos com 6-fosfogliconolactonase (pgl)"
AR092076A1 (es) Proteinas homodimericas
WO2009073618A3 (en) Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure
WO2016138534A3 (en) Antisense-induced exon2 inclusion in acid alpha-glucosidase
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
EP4406557A3 (en) Materials and methods for improving gastrointestinal function
WO2012027411A3 (en) Compositions and uses of materials with high antimicrobial activity and low toxicity
EP2502618A3 (en) Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
WO2009126292A3 (en) Biologically active peptidomimetic macrocycles
GB2488500B (en) Substances for use as anti-depressants or as a learning motivation improver
EA201170878A1 (ru) Полипептиды с ксиланазной активностью
DK2337796T3 (da) Rekombinante proteiner, som har hæmostatisk aktivitet og er i stand til at inducere trombocytaggregation
WO2011008823A3 (en) Peptide-mediated non-covalent delivery of active agents across the blood brain barrier
WO2011008495A3 (en) Arginase formulations and methods
EP4403197A3 (en) Injectable formulations for organ augmentation
MX337315B (es) Composiciones y metodos para tratar y/o prevenir enfermedad cardiovascular.
WO2015031726A3 (en) Engineered primate l-methioninase for therapeutic purposes

Legal Events

Date Code Title Description
FG Grant or registration